Vildagliptin - Wikipedia, the free encyclopedia
Vildagliptin (previously identified as LAF237, trade name Galvus) is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor ...
Dipeptidyl peptidase-4 inhibitor - Wikipedia, the free encyclopedia
See pages of this article for Galvus aka LAF237 (Novartis) and Januvia aka MK-0431 (Merck) Nielson, Loretta L. (15 May 2005), "Incretin mimetics and DPP-IV inihibitors for the ...
Galvus Combination Lowers HbA1c By Up To 2.8%
Galvus combined with pioglitazone reduces HbA1c by up to 2.8% in type two diabetes patients, say Galvus makers, Novartis. Compared with pioglitazone alone, with the Galvus ...
Eucreas®, a single-tablet combination of Galvus® and metformin, set ...
View all media releases. February 25, 2008 07:15 CET. Eucreas®, a single-tablet combination of Galvus® and metformin, set for launch in first EU countries as new treatment for ...
vildagliptin (Galvus)
Galvus® (vildagliptin) is a drug in a new class of oral diabetes medications, called DPP-4 inhibitors. It is available in Europe, but not in the United States.
Januvia vs Galvus - Treatment drugs for Type 2 Diabetes
Galvus is still to receive its approval from the FDA. It works in the same manner as Januvia. Galvus also comes under the class of drugs called the DPP- 4 inhibitors which are also ...
Novartis CEO: Galvus' future is uncertain - FierceBiotech
Long delayed by a wary FDA, Novartis CEO Daniel Vasella (photo) now says that the diabetes drug Galvus may never be refiled for approval in the U.S. Safety issues arising around ...
Galvus safety issues could keep it out of U.S.: analyst - Nov. 13 ...
Novartis' troubled diabetes drug Galvus might never make it to the U.S., said an analyst, though the company disputed the comments as "pure speculation."
Galvus superior to Actos with regard to weight, says Novartis
Galvus superior to Actos with regard to weight, says Novartis 21/09/2007 www.pharmatimes.com New data show Novartis' DPP-4 inhibitor Galvus is as good as Takeda's Actos at ...
Galvus’ EU Launch Held Up by Safety Update to Physician Labeling
Novartis’ diabetes drug Galvus hit another roadblock as its launch in the European Union (EU) will be delayed until the firm receives approval for updated physician labeling.
